Background : Several recent reports have connected protein methylation with differentiation. Furthermore, the BTG/TOB proteins have also been implicated in such control. BTG1 and 2 have been shown to interact with PRMT1 (predominant cellular arginine N-methyltransferase of type I).
Introduction
The BTG/TOB protein family is characterized by a common signature: two well conserved boxes A and B localized in their N-terminal region (Guéhenneux et al . 1997) . Several members of the BTG/TOB family (BTG1, BTG2/TIS21/PC3, PC3B, BTG3/ANA, TOB, TOB2) are thought to play a role in cell cycle negative control since their RNA expression is associated with different cell cycle arrest processes (differentiation commitment, genotoxic treatment, P53-regulated expression of BTG2 ... ) and their in vitro ectopic over-expression is anti-proliferative (Buanne et al . 2000; Fletcher et al . 1991; Iacopetti et al . 1999; Ikematsu et al . 1999; Matsuda et al . 1996 Matsuda et al . , 2001 Montagnoli et al . 1996; Rodier et al . 1999; Rouault et al . 1992 Rouault et al . , 1996 Seo et al . 1999; Yoshida et al . 1998 Yoshida et al . , 2000 . Moreover, BTG2 -mutated ES cells (Embryonic Stem cells) present an altered G2 / M block when treated with genotoxic agents (Rouault et al . 1996) . The mechanisms underlying this inhibition remain to be deciphered, but it was recently proposed that BTG2/ TIS21/PC3 over-expression maintained Rb protein in its hypophosphorylated form, thus preventing cell growth (Guardavaccaro et al . 2000) .
Although the participation of the BTG/TOB proteins in cell cycle control has now been firmly established, the biochemical mechanisms involved remain to be determined. The only significant data currently available on the function of BTG/TOB proteins have been provided by the discovery of their partners. TOB, through its non-BTG/TOB homologous domain, interacts with the growth factor receptor erbB2 and modulates the signal elicited by Epidermal Growth Factor (Matsuda et al . 1996) . Several recent studies have reported the physical association of BTG/TOB proteins with transcription factors: BTG1 and 2, BTG3/ANA, TOB and TOB2 with CAF1, BTG1 and 2 with HoxB9 and TOB with SMAD proteins (Bogdan et al . 1998; Ikematsu et al . 1999; Prevot et al . 2000; Rouault et al . 1998; Yoshida et al . 2000 Yoshida et al . , 2001 . The exact role of BTG/ TOB proteins within these different complexes is not completely understood yet. Nevertheless, it should be noted that TOB interferes with the SMAD machinery and inhibits the effects of SMAD, at least during osteoblast formation ( Yoshida et al . 2000) .
It has also been shown that BTG1 and 2 proteins interact with a protein arginine N-methyltransferase (i.e. PRMT1) and positively modulate its activity (Lin et al . 1996) . This observation is important since arginine methylation by type I arginine N-methyltransferase is a common post-translational protein modification that seems to be catalysed predominantly by PRMT1 (Gary & Clarke 1998; Pawlak et al . 2000; Tang et al . 2000a) .
Type I arginine N-methyltransferase activity promotes the formation of ω -monomethylarginine and asymetric ω -N G , N G -dimethylarginine. The function of this modification is not known, but there is evidence suggesting that it may contribute to RNA processing, protein shuttling and to the regulation of transcription (Chen et al . 1999; Gary & Clarke 1998; Koh et al . 2001; Shen et al . 1998; Yoshida et al . 2000) . However, the inhibition of PRMT1 activity by global protein methylation inhibition prevents the NGF (Nerve Growth Factor)-stimulated differentiation of PC12 cells into neurones and PRMT1 (-/-) mouse embryos fail to develop (Cimato et al . 1997; Pawlak et al . 2000) . As mentioned above, PRMT1, the first arginine N-methyltransferase characterized, seems to be the enzyme that catalyses most of the type I methylation reactions. Herschman's group showed, using biochemical methods, that the major type I activity could be attributed to PRMT1 ( Tang et al . 2000a) . Furthermore, PRMT1 mutated cells also display a very reduced type I arginine N-methyltransferase activity (Pawlak et al . 2000) . PRMT1 binds to the cytoplasmic domain of the IFNAR1 chain of the interferon receptor and is a major effector of interferon antiproliferative signalling through its interaction with STAT1 (Abramovich et al . 1997; Mowen et al . 2001) . Recently, ILF3, poly(A)-binding protein II, hnRNP A2 and HMW-FGF2 (Fibroblast Growth Factor 2) were proposed as PRMT1 substrates (Klein et al . 2000; Nichols et al . 2000; Smith et al . 1999; Tang et al . 2000b) . Taken together, these results suggest that PRMT1 plays an important role in a number of highly conserved evolutionary pathways.
PRMT1 and some of the BTG/TOB proteins have already been shown to be involved in the negative control of the cell cycle, apoptosis and differentiation. For this reason, we hypothesized that their association might be relevant in this context. In this paper, we first report molecular studies of PRMT1 and BTG/TOB protein interactions, and then analyse their functional consequences.
Results

Molecular analysis of PRMT1 interaction with BTG/TOB proteins leads to the identification of boxC
In this study, we used the two-hybrid interaction system developed by Fields & Song as previously described (Fields & Song 1989; Rouault et al . 1998) . To screen for BTG proteins which are able to interact with PRMT1, the Y190 pPC86-PRMT1 (PRMT1 fused to GAL4 activation domain) expressing yeast strain was transformed with BTG1, BTG2/TIS21/PC3 and BTG3 pPC62 expressing vectors (BTG proteins fused to GAL4 DNA binding domain). When the two proteins physically interact, the resulting yeast strain grows on L/W/ H depleted SC medium and produces a β -galactosidase activity that can be revealed by a yeast colony filter assay (Chevray & Nathans 1992) . In this system, BTG1 and BTG2, but not BTG3 associated with PRMT1. BTG1 and BTG2 are very homologous proteins, their only significant difference being a small insertion in the C-terminal regions (Rouault et al . 1992 ). We then gradually deleted the BTG1 in order to delineate the region necessary for this interaction. As shown in Fig. 1A , the required sequence turned out to be a 10 amino acid region juxtaposed to the previously described boxB, which constitutes, along with boxA, the structural signature of the BTG/TOB family (Guéhenneux et al . 1997) . However, when this peptide (DGSICVLYEA), hence named boxC, was fused to the GAL4 DNA binding domain (pPC62 vector), no interaction with PRMT1 could be detected (Fig. 1A) . Sequence similarity searches did not reveal the presence of the boxC peptide in other proteins. However, it should be noted that, among BTG/TOB members, TOB and TOB2 possess a sequence close to their boxB that is partially similar to boxC (GXXXVLYXX) (Matsuda et al . 1996; Ikematsu et al . 1999) .
We then performed in vitro association assays commonly known as 'pull-down' experiments (Rouault et al . 1998) . Several purified GST (Glutathione S-Transferase) fusion proteins were incubated with labelled PRMT1; their retention capacity (after extensive washing) was revealed by autoradiography (Rouault et al . 1998) . A specific retention of S 35 -methionine labelled PRMT1 was observed with GST-BTG2, but not with GST-BTG3 (Fig. 1B) . This confirmed the fact that BTG3 does not interact with PRMT1. Furthermore, GSTboxCdeleted-BTG2 protein, contrary to the native GST-BTG2, did not interact with PRMT1 in this system. These results suggest that boxC is necessary BoxC blocks the stimulating effect of BTG2 on methyltransferase activity
The following experiments were designed to determine the effect of boxC addition on type I arginine methyltransferase activity (Ghosh et al . 1988; Lin et al . 1996) . PRMT1 was recently shown to play a major role in type I activity (90% of total type I activity) (Pawlak et al . 2000; Tang et al . 2000a) . Furthermore, boxC is present only in BTG1 and BTG2/TIS21/PC3 proteins which positively modulate PRMT1 activity (Lin et al . 1996) . Therefore, it is legitimate to consider that the possible modification of methyltransferase activity by boxC addition will predominantly reflect the effect of BTG on PRMT1 enzymatic activity. Type I arginine methyltransferase activity was determined in a standard reaction mixture using histone H2A as the methyl acceptor substrate, PC12 cytosolic extracts and SAM (S-adenosyl-l -(methyl-3 H)methionine) as the methyl donor (Ghosh et al . 1988; Lin et al . 1996) . BoxC was fused with penetratin (see next paragraph) (Derossi et al . 1998) . Penetratin was used in control experiments. Peptide concentrations (0.2 and 0.3 m m ) were determined in the range of previously described competition experiments in methylation assays using synthetic peptides (0.5 m m in this case) (Klein et al . 2000) . Consistent with the results of Lin and co-workers, the addition of GST-BTG2 protein to the reaction mixture increased arginine methyltransferase activity (Fig. 2 , lanes 1 and 2). BoxC inhibited this activity; this inhibition increased in parallel with boxC concentration (lanes 1, 3 and 5). The control peptide (penetratin) used at the same concentration did not modify this activity (lanes 1, 7 and 8). Competition experiments between the boxC peptide and BTG2 showed that BTG2 could still up-regulate type I activity in the presence of a 0.2 m m concentration of boxC (lanes 3 and 4). However, the magnitude of type I activity up-regulation by BTG2 was inferior to that observed in the absence of boxC ( lane 2) or in controls (lane 1). At 0.3 m m , BTG2 could not counteract boxC, and type I activity was nearly abolished ( lanes 5 and 6). These results suggest that boxC competitively prevents the enzymatic activation of PRMT1 by BTG proteins. We conclude that the interaction with BTG proteins is important for PRMT1 activity or at least arginine methyltransferase type I activity, since boxC alone strongly inhibits this activity in this system.
BoxC interferes with the PC12 cell differentiation programme
To further investigate the functional relevance of PRMT1/BTG-mediated methylation, we treated PC12 cells with boxC peptide, since we had previously shown that its addition impeded BTG / PRMT1 association and BTG2 / TIS21/PC3-controlled methylation. We chose the PC12 cell line because the inhibition of protein methylation had been described as preventing the differentiation of PC12 cells (Cimato et al . 1997) . Furthermore, PC12 cells enabled the characterization of BTG2/TIS21/PC3 which is up-regulated during NGFinduced differentiation (Bradbury et al . 1991) . All these data led us to speculate that the BTG/PRMT1 pathway could play a key role in the control of neural differentiation.
We used the penetratin system for intracellular delivery of the peptide boxC (Derossi et al . 1998 ). Penetratin, 16 amino acids corresponding to the third helix of the antennapedia protein homeodomain, can translocate across membranes and be internalized by cells. Penetratin is used as a vector for transferring compounds into cells and thus address their biological activity. We therefore fused boxC with penetratin, and then analysed its in cellulo effect.
In a preliminary set of experiments, we checked PC12 cells, either treated or not by NGF, for internalization of the penetratin-boxC peptide. Penetratin and penetratin fused with the 10 amino acids of BTG3, corresponding to the sequence located in the boxC position in BTG1 and 2, were used as controls. The peptides were biotinylated to reveal their internalization through FITCconjugated streptavidin staining. These experiments showed that the peptides effectively penetrated into PC12 cells at a concentration of 15 µ m , close to that used previously by Derossi on neurones (22 µ m ) (data not shown) (Derossi et al . 1996) .
Having established that the peptides had entered the recipient cells, we used unbiotinylated peptides in the following experiments. Neither penetratin-boxC nor controls interfered with the normal growth of PC12 cells in the absence of NGF (data not shown). We then treated PC12 cells with NGF. As shown in the control (Fig. 3A) , after 4 days of NGF treatment, PC12 cell differentiation was readily observable and the cells exhibited a large number of neurites. The simultaneous addition of a control peptide did not alter differentiation. In the presence of boxC, cells formed clumps of various sizes and neurite outgrowth was still observed (Fig. 3A) . We then hypothesized that this phenomenon could be associated with apoptosis, since interference in differentiation often leads to cellular death, in particular during neuronal differentiation (Poluha et al. 1996) . We performed TUNEL assays on the NGF-treated PC12 cells cultured with the different peptides. It appeared that penetratin-boxC addition resulted in an increased rate of apoptosis (Fig. 3B) . The magnitude of apoptosis in our experiments (15%) was even greater than that observed in neuroblastoma SH-SY5Y cells, where the activity of the anti-proliferative P21 gene is prevented by anti-sense oligonucleotides (Poluha et al. 1996) . These authors reported an apoptosis rate of 10% which they considered highly significant. As these effects only occurred in the presence of NGF, it led us to think that boxC interfered with the control of differentiation. This suggests that the BTG / PRMT1 association (prevented by boxC in these experiments) could be of fundamental importance during the neuronal differentiation of PC12 cells.
We then sought to determine whether the pattern of methylation could be altered during the course of these experiments and thus reveal the molecular consequences of boxC addition. We investigated the endogenous protein methylation of NGF-treated PC12 cells with and without boxC, following procedures described by others (Cimato et al. 1997; Tang et al. 2000a ). The PC12 cell extracts were incubated in a standard reaction, and then analysed for possible discrepancies in protein labelling intensities. It should be noted that only the proteins that are actively methylated in the course of the labelling are detected in these experiments, and that proteins already extensively methylated are not detected, unless they are previously hypomethylated by drugs such as adenosine dialdehyde. Since protein methylation is necessary for PC12 cell differentiation to occur, we chose to focus on newly methylated proteins that were more likely to be involved. The pattern of methylation that we observed was more or less identical to that obtained by Cimato under the same conditions, with high labelling intensities at 20 and 30 kDa (Cimato et al. 1997) (Fig. 4) . The only significant modification we noticed after boxC addition was the decreased methylation of a 20 kDa protein (Fig. 4) . This protein has the same size as a recently characterized and highly arginine-methylated protein (Gu et al. 1999) . So, boxC addition on PC12 cells prevents the methylation of a 20 kDa protein, presumably by interfering with PRMT1/BTG association.
BoxC addition inhibits neuronal cell differentiation
A link between methylation and neuronal differentiation has already been described (first two paragraphs of the Results section and Cimato et al. (1997) ) and postmitotic neurones were shown to preferentially express BTG2/TIS21/PC3 (Iacopetti et al. 1999) . To determine the functional relevance of BTG/PRMT1 association during neuronal differentiation, we examined the boxC effect on ES cells. We chose to work on ES cells because, depending on culture conditions, these cells can differentiate into many lineages in vitro. In particular, neuronal cells can be obtained either isolated or as aggregates of various sizes (Fraichard et al. 1995) .
First, differentiated and undifferentiated ES cells were treated with the biotinylated peptides. In all of the conditions tested, peptides were detected in the cells. It is noteworthy that peptides did not induce any changes in the proliferation rate of undifferentiated ES cells (data not shown). Retinoic acid is known to trigger the differentiation Figure 4 Methylation inhibition of a 20 kDa protein by boxC. Changes in the protein methylation pattern were tested using cytosol extracts from PC12 cells treated as indicated below the autoradiography (4 h). In these experiments, only endogenous methylation was assessed, since no external substrate was added in the cytosolic extracts. of ES cells into a variety of cell types and, more specifically, into endoderm-like and fibroblast-like cells (Smith 1991) . After ES cells had differentiated into embryoid bodies, retinoic acid and the different peptides were added. The morphology of the different cell types did not change notably. However, under these conditions, neuronal-like cells did not develop following boxC addition (data not shown). Furthermore, when boxC peptide was added to a long-term culture (8 days) so as to allow complete differentiation, a neurite size reduction could was noted after 12 h, and a complete disappearance of the soma after 36 h (Fig. 5, lower part) . Control peptides (BTG3 and penetratin) did not modify the morphology of these neuronal-like cells (Fig. 5) . MAP2 antibody that detects neuronal cells was used (Binder et al. 1986 ). The upper right part of Fig. 5 illustrates this staining on differentiated ES cells. After the boxC treatment, only a few MAP2-positive cell aggregates were present. Furthermore, following boxC treatment the aggregates were surrounded by a reduced number of isolated cells (an average of 29 cells per aggregate vs. 88 cells with control peptides) ( Table 1) . Therefore, these results confirm and strengthen the idea that the PRMT1/BTG methylation pathway is involved in neurogenesis or at least in maintaining neuronal cells in a differentiated state.
To more precisely measure the observed effect, we used ES cell culture conditions leading to the preferential generation of neuronal cells, as described by Lee et al. (2000) . In this differentiation process, the proliferation of neuronal precursors was sustained by bFGF. During this phase, the addition of any of the synthetic peptides induced no effect (growth rate, apoptosis, morphological phenotype). When bFGF was withdrawn, the cells stopped proliferating, and then eventually entered terminal differentiation (Lee et al. 2000) . At this stage, penetratin-boxC addition led to increased rates of apoptosis as well as to the disappearance of MAP2-positive cells (post-mitotic neurones) in the same proportion (TUNEL assay, Fig. 6 ). Thirty-two per cent of cells treated with boxC were in apoptosis vs. 7% of cells treated with the control peptides ( Table 2) . These results showed that boxC addition interfered with terminal neuronal differentiation and induced apoptosis in cells engaged in the neuronal lineage.
Discussion
BTG/TOB proteins are highly conserved through evolution and seem to be related with the negative control of the cell cycle, although their precise function remains to be determined. To broaden our knowledge on BTG/ TOB proteins and on the signal transduction pathways they might control, partners have actively been sought for. For instance, all BTG/TOB proteins seem to be associated with CAF1 (Bogdan et al. 1998; Ikematsu et al. 1999; Rouault et al. 1998; Yoshida et al. 2001) .
CAF1 belongs to a transcriptional regulatory complex and has recently been shown to be involved in the major cytoplasmic deadenylase in yeast (Tucker et al. 2001) . However, the actual role of CAF1 remains to be elucidated and this interesting result does not shed any light on the role of the BTG/TOB family in this context. Another relevant study reported that BTG1 and 2 are physically associated with PRMT1 and positively regulate its activity, PRMT1 being the predominant cellular arginine methyltransferase of type I (Lin et al. 1996; Pawlak et al. 2000; Tang et al. 2000a ).
Considering the above data, we decided to further analyse the nature and the functional consequences of the interaction between BTG/TOB family members and PRMT1. The present results show that a region of 10 amino acids found only in BTG1 and BTG2, named boxC, is required to achieve the exclusive association between BTG1 and 2 and PRMT1, since other members of the BTG/TOB family, which do not contain this sequence, do not seem to interact with PRMT1. It is noteworthy that CAF1 association with BTG/TOB proteins is mediated by boxB, one of the BTG/TOB family signatures (Guéhenneux et al. 1997; Rouault et al. 1998 ).
Lin and co-workers previously suggested that BTG1 and 2 play an important role in regulating PRMT1 methyltransferase activity (Lin et al. 1996) . We hypothesized that peptide boxC would constitute a good tool for the analysis of this interaction. We studied the effect of boxC addition in a standard reaction using histone H2A as a substrate, a reaction which mostly reflects PRMT1 activity. We showed that boxC addition inhibited the stimulating effect of exogeneously added BTG2. Furthermore, the endogenous methylation activity (without BTG2 addition) was also reduced. These results suggest that boxC competes with BTG1 and 2 and thus prevents PRMT1 activation. These observations confirm the work of Lin and co-workers, who suggested that BTG1 and 2 are the major coactivators of PRMT1 (Lin et al. 1996) . This means that the enhanced expression of ES cells were preferentially differentiated into neuronal cells according to (Lee et al. 2000) . Different peptides (15 µm) were added during terminal differentiation (after bFGF withdrawal). MAP2 antibody staining and TUNEL assays were performed 2 days later.
BTG1 and 2 observed during different processes (cell cycle arrest following stress injuries, differentiation) might stimulate PRMT1 methyltransferase activity and that PRMT1 could thus be a major effector of these phenomena. We suggest that BTG1 and 2/PRMT1 might constitute a new signal transduction pathway that can be inhibited by the addition of boxC.
To determine the physiological relevance of this pathway, we fused boxC with a cargo peptide, penetratin (Derossi et al. 1998) . We chose PC12 cells as a cellular model. BTG2/TIS21/PC3 expression is NGF-induced in PC12 cells (Bradbury et al. 1991) . Furthermore, it has been demonstrated that protein methylation was necessary for PC12 cells to readily differentiate (Cimato et al. 1997) . BoxC addition on undifferentiated PC12 cells had no effect. By contrast, differences in cell morphology were observed when NGF and boxC were added simultaneously: the differentiated cells formed clumps. We then sought to determine whether this could be due to the induction of apoptosis, since it had been shown that the inhibition of P21 expression led to the apoptotic cell death of neuroblastoma cells triggered to differentiate (Poluha et al. 1996) . It is noteworthy that P21 is the prototype of an anti-proliferative gene involved in numerous processes such as genotoxic response and differentiation. In our model, we observed 15% of boxCinduced apoptosis. This rate is even greater than the 10% observed with P21 inhibition. BTG2 expression is induced during PC12 cell differentiation and is a predominant co-activator of PRMT1 (present results and Lin et al. (1996) ). Therefore, we suggest that BTG1 and 2/PRMT1-driven arginine methylation could partly account for the essential role of protein methylation during PC12 cell differentiation (Cimato et al. 1997) . Furthermore, even if the methylation of proteins seems to be a constitutive process, these results suggest the existence of a dynamic control. In this context, we noticed that boxC addition on PC12 cells induced the rapid loss of methylation of a 20 kDa protein, which might correspond to the unidentified 20 kDa arginine-methylated protein described by Gu et al. (1999) . This experiment also indicated that boxC interferes with methyltransferase activity, not only when it is added on cellular extracts but also when it is already present in the cell. The nature of this 20 kDa protein remains to be determined, but it can be postulated that it regulates a process of highest importance during PC12 cell differentiation.
Several studies point to the role of the BTG/PRMT pathway in neuronal differentiation in vivo. Iacopetti and co-workers (Iacopetti et al. 1999) have shown that BTG2 is expressed in post-mitotic neuronal cells. Studies of PRMT1 +/-mice reveal a strong expression at early stages of neurogenesis (midline of the neural plate) (Pawlak et al. 2000) . In order to determine the selective influence of boxC on neuronal differentiation, we used ES cells differentiated into embryoid bodies and treated with retinoic acid, which give rise to different cell lineages (neuronal, haematopoeitic, cardio-muscular, endothelial, etc.) . Following boxC treatment, we observed the selective disappearance of cells that expressed MAP2, which corresponded to postmitotic neuronal cells (Binder et al. 1986) . Therefore, the BTG1 and 2/PRMT1 pathway seems to play a predominant role in the control of neuronal differentiation. We chose to test this hypothesis further using cell culture conditions that resulted in the preferential development of neuronal cells (Lee et al. 2000) . In this assay, boxC induced a massive apoptosis of terminally differentiated neuronal cells, thus confirming the important role of BTG/PRMT1 in this process. Nevertheless, this work does not enable us to decipher whether arginine methylation mediated by PRMT1/ BTG controls an anti-apoptotic signal, or whether it is only necessary for the neuronal differentiation process to be maintained. In the latter case, differentiated neuronal cells would be submitted to an uncomplete signal due to the lack of arginine methylation. They would thus degenerate via apoptosis. It should be noted that BTG proteins have been implicated in both mechanisms. For example, BTG1 has been shown to stimulate myoblast differentiation (Rodier et al. 1999) , and the P53-induced gene BTG2 is thought to play a role in G2/M control following genotoxic treatment (Rouault et al. 1996) . PRMT1 is thought to play a key role in numerous signal transduction pathways. For instance, PRMT1 is associated with the interferon IFNAR1 receptor and is required for interferon-induced transcription by STAT1 (Mowen et al. 2001) . Several PRMT1-methylated proteins have also been described. Although the role of this post-translational modification is unknown, these targets could constitute anchors to delineate the controlled pathways. This report focuses on the PRMT1/BTG pathway and on its involvement in neurogenesis. One of the next goals will be to determine the nature and role of the proteins methylated by PRMT1 during differentiation.
Experimental procedures
Two-hybrid experiments
We used pPC62-BTG vectors as previously described (Rouault et al. 1998) (Fig. 1A) . The PRMT1 rat cDNA was obtained by RT-PCR using primers PRMT1-353 and PRMT1-1 according to the PRMT1 sequence U60882 available in GenBank. We followed the Superscript II (Gibco-BRL) and Promega protocols. The cDNA was then cloned in pPC86 (SalI/Not I).
Oligonucleotides: BTG1-1 aggtcgaCATCCCTTCTACACCCGG BTG1-17 gctctagaTCCAACAGACTATATC BTG1-117 catctagactaCTCTCCAATTCTGTAGGACAC BTG1-129 gctctagacTGGTGAGGCTTCATACAGCAC BTG1-154 gctctagacGAGAAGTTCCTCCTTACAGCT boxC tcgacgGATGGCTCCATCTGTGTGCTGTATGAAGCCTCACCAtagt and ctagactaTGGTGAGGCTTCATACAGCACACAGATGGAGCCATCcg BTG2-1 aggtcgaACGGGAAGGGAACC BTG2-158 gctctagaAGGGCCTAGCTGGAGAC BTG3-1 aggtcgacGAAGAACGAAATTGCGGCT BTG3-251 gctctagaCTAGTGAGGTGCTAACAT PRMT1-1 gagtcaccATGGCGGCAGCCGAGGCCGCGAA PRMT1-353 gagcggccGCCAGCCTGGCACCTCCTCAGC All plasmids were sequenced using sequenase 2.0 (US Biochemical Corp.).
The two-hybrid experiments were performed as previously described (Rouault et al. 1998 ) except for aminotriazol (20 mm), which was added to L/W/H (Leucine/Tryptophan/Histidine) depleted SC medium.
GST pull-down experiments
The coding sequences of BTG2 and BTG3 were inserted into the pGEX-ET expression vector (Pharmacia).
Deletion of boxC in pPC62-BTG2 was performed by mutagenesis using the USE Mutagenesis Kit (Pharmacia), with the following primer: CCTACCGCATTGGGGAGGCGCCACTGGCCGCC;
The deleted boxC was situated between the underlined nucleotides. PRMT1 cDNA was subcloned from pPC86-PRMT1 into the SalI/Not I sites of pBluescript. In vitro [ 35 S]methionine-labelled PRMT1 was produced using the TNT T7 polymerase kit (Promega). GST pull-down experiments were performed as previously described (Rouault et al. 1998) .
Methylation assays
PC12 cell extracts were prepared essentially as previously described (Lin et al. 1996) , except for the cell disruption, which was performed by freeze-thawing four times in liquid nitrogen.
The 50 µL reaction contained: 25 mm Tris, 1 mm EDTA, 1 mm EGTA at pH 7.4, 5 µCi S-adenosyl-l-(methyl-3 H)methionine (SAM) (NEN Dupont, 85 Ci/mmol), 50 µg of cytosol extract, and if required 100 µg of histone H2A (Sigma) as substrate. Ten micrograms of GST-BTG2 or the peptides penetratin or penetratin-boxC were added at different concentrations in some methylation reactions. These peptides were synthesized by Syntem (Nîmes, France). The sequence of penetratin is RQIKIWFQR-RMKWKK (Derossi et al. 1998 ) and that of penetratin-boxC is RQIKIWFQRRMKWKKDGSICVLYEA.
The reactions were incubated at 30 °C for 45 min, and then stopped by the addition of 10 µL of Laemmli buffer. The samples were run on 10% SDS-PAGE. The gel was fixed (25% isopropanol / 10% acetic acid) for 30 min, soaked in Amplify (Amersham) for 30 min, then dried and exposed.
Cell line and culture
PC12 cells were cultivated essentially as in Cimato et al. (1997) . The cells were seeded, and then treated with NGF (50 ng/mL) (Sigma). One day after seeding, peptides penetratin and penetratinboxC (15 µm) were added on to PC12 cells.
Embryonic Stem (ES) cells (ENS cell line (Gauthier et al. 1999 )) were maintained routinely on feeder cells (40 Gy irradiated primary fibroblasts) in medium (BHK-21, Gibco BRL) supplemented with 10% foetal calf serum, 0.1 mm β-mercaptoethanol, 1 mm sodium pyruvate, 1% nonessential amino acids, 2 mm glutamine, 0.1 mg/mL penicillin-streptomycin and 2000 U/mL of human leukaemia inhibitory factor. ES cells were induced to differentiate by culture on to nonadherent Petri dishes (10 4 cells in 10 mL of LIF-deprived culture medium) for 5-8 days to allow for the formation of embryoid bodies. Embryoid bodies were then plated on tissue culture dishes coated with 0.1% gelatin, either with 10 -6 m retinoic acid for 5 -20 days, or according to the protocol developed by Lee et al. (2000) to select and expand neuronal cells, except that FGF8 was not added to the expansion medium.
Immunocytochemistry
Cells were washed in PBS, then fixed in 70% ethanol for 10 min, washed three times for 5 min each in TBS and dehydrated in 95% ethanol / 5% acetic acid for 15 min at -20 °C, and then washed three times in TBS. Cells were incubated for 20 min with 20% normal goat serum, washed three times in TBS, then incubated for 2 h with MAP2 monoclonal antibody (Sigma ref. M4403, diluted at 1/100 in TBS, 5% glycerol, 0.2% Tween, 2% BSA). MAP2 antibody is raised against microtubule associated proteins A and B, two isoforms that are abundant in the adult mammalian central nervous system. Cells were washed three times in TBS, and then incubated for 2 h with Cy3-conjugated goat anti-mouse antibody (Interchim ref. 115165003 , diluted at 1/200 in TBS, 5% glycerol, 0.2% Tween, 2% BSA) and then washed three times in TBS; after 2 min incubation with bis-benzimide (diluted at 0.5 µg/mL in H 2 O), cells were washed three times in TBS, and then mounted in Vectashield ( Vector Laboratories).
Apoptosis detection
An in Situ Cell Death Detection kit (Roche) was used following the manufacturer's instructions for adherent cells except that cells were fixed in 70% ethanol for 10 min. One thousand cells were counted in each experiment.
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